Study to investigate CSL689 in subjects with haemophilia (A or B)

• Research type

  Research Study

• Full title

  A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors.

• IRAS ID

  142282

• Contact name

  Pratima Chowdary

• Contact email

  p.chowdary@nhs.net

• Sponsor organisation

  CSL Behring GmbH

• Eudract number

  2012-001309-26

• REC name

  London - Bloomsbury Research Ethics Committee

• REC reference

  14/LO/0009

• Date of REC Opinion

  6 Mar 2014

• REC opinion

  Further Information Favourable Opinion